Pilot Evaluation of the Unsupervised, At-Home Cogstate Brief Battery in ADNI-2.
Pilot Evaluation of the Unsupervised, At-Home Cogstate Brief Battery in ADNI-2.
复制标题
DOI：
10.3233/jad-210201
复制
发表时间：
2021
期刊：
影响因子：
--
通讯作者：
Alzheimer’s Disease Neuroimaging Initiative
中科院分区：
文献类型：
--
作者：
Edgar CJ;Siemers E;Maruff P;Petersen RC;Aisen PS;Weiner MW;Albala B;Alzheimer’s Disease Neuroimaging Initiative
需要可行的、可扩展的评估来检测认知障碍和衰退。 Cogstate Brief Battery (CBB) 经过针对阿尔茨海默病 (AD) 的验证，并且可以在无人监管和自带设备环境下使用。 CBB 已显示出在家中自我完成的可用性，但尚未在 AD 多中心临床试验中以这种方式使用。该试点项目的目标是评估在 24 个月内在家自行完成阿尔茨海默病神经影像计划 (ADNI) 中 CBB 的可行性。 CBB 被纳入 ADNI-2 中，作为认知正常 (CN) 和轻度认知障碍 (MCI) 参与者的试点，受邀在诊所进行评估，然后在家进行为期 24 个月的随访。分析数据以探索可接受性/可用性、诊所和家庭评估的一致性以及有效性。收集了 104 名同意提供 CBB 数据的参与者（46 名 CN、51 名 MCI 和 7 名 AD）的数据。仅对 CN 组和 MCI 组进行了后续分析。首次诊所监督评估和首次在家无人监督评估的测试完成率均为 100%，几乎不需要重复执行。然而，随着时间的推移，可用的后续数据急剧下降。诊所和家庭评估之间具有良好的一致性，效应大小差异不显着且较小（Cohen’s d 在 -0.04 和 0.28 之间），相关性总体中等（r = 0.42 至 0.73）。已知组的有效性也得到支持（11/16 与 Cohen 的 d≥0.3 比较）。这些数据证明了将 CBB 用于无人监督的家庭测试（包括 MCI 组）的可行性。应用评估来支持长期合规性的最佳方法仍有待确定。
There is a need for feasible, scalable assessments to detect cognitive impairment and decline. The Cogstate Brief Battery (CBB) is validated for Alzheimer’s disease (AD) and in unsupervised and bring your own device contexts. The CBB has shown usability for self-completion in the home but has not been employed in this way in a multisite clinical trial in AD. The objective of the pilot was to evaluate feasibility of at-home, self-completion of the CBB in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) over 24 months. The CBB was included as a pilot for cognitively normal (CN) and mild cognitive impairment (MCI) participants in ADNI-2, invited to take the assessment in-clinic, then at at-home over a period of 24 months follow-up. Data were analyzed to explore acceptability/usability, concordance of in-clinic and at-home assessment, and validity. Data were collected for 104 participants (46 CN, 51 MCI, and 7 AD) who consented to provide CBB data. Subsequent analyses were performed for the CN and MCI groups only. Test completion rates were 100%for both the first in-clinic supervised and first at-home unsupervised assessments, with few repeat performances required. However, available follow-up data declined sharply over time. Good concordance was seen between in-clinic and at-home assessments, with non-significant and small effect size differences (Cohen’s d between -0.04 and 0.28) and generally moderate correlations (r = 0.42 to 0.73). Known groups validity was also supported (11/16 comparisons with Cohen’s d≥0.3). These data demonstrate the feasibility of use for the CBB for unsupervised at-home, testing, including MCI groups. Optimal approaches to the application of assessments to support compliance over time remain to be determined.